Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033720 | 0.84 | MTOR (0.33) | — | |
| SCHEMBL2153565 | 0.82 | CA1 (0.44) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL17740107 | 0.74 | CA1 (0.41) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL18697369 | 0.73 | CA1 (0.44) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL10657535 | 0.73 | CA1 (0.47) | MAPTCA1CA2CA4CES2 | |
| SCHEMBL19484370 | 0.73 | MAPT (0.41) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL15763915 | 0.72 | MAPT (0.43) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL26770524 | 0.71 | CA1 (0.43) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL1994881 | 0.71 | CA1 (0.43) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL319016 | 0.71 | CA1 (0.39) | MAPTKDM4EALDH1A1HTTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611284-B2 | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-04-04 | — | — | US | disclosed |
| US-9611284-B2 | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-04-04 | — | — | US | disclosed |
| US-20130157984-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-06-20 | — | — | US | disclosed |
| US-20130157984-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157984-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | PTGES, PTGFR, PTGIS | MAPT 4789/4885KDM4E 2945/4885ALDH1A1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.